• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

    8/3/22 2:53:00 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email

    BRIDGEWATER, N.J., Aug. 3, 2022 /PRNewswire/ -- Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses.

    Olivier Bogillot becomes Head of U.S. General Medicines. Bogillot, most recently President of Sanofi France, will lead the business unit responsible for serving the Diabetes, Cardiovascular and Transplant communities effective September 1.

    Bogillot joined Sanofi in 2015, and has held various positions within the company, including as Executive Director of Global Policy based in the U.S. and Chief of Staff to the CEO. In March 2020, he was appointed President of Sanofi France, where he has led the Strategic Committee and the Country Council of Sanofi France, coordinating all the activities of the French subsidiary and representing the Group to French Authorities and professional organizations.

    Bogillot held key roles in market access at Merck KGaA, Amgen and Bristol-Myers Squibb before being appointed Chief of Staff to the Director at the Greater Paris Regional Health Agency in 2009. He subsequently joined the Presidency of the French Republic in 2011, as advisor for health, dependency, and social policies.

    He holds a PhD in Economics (University of Lyon I), a master's degree in Health Economics and Public Health and a degree in Molecular Biology and Physiology.

    Deborah Glasser is the new Head of Vaccines, North America, responsible for the company's industry-leading vaccines business in the U.S. and Canada.

    Before taking on the role at Sanofi on June 20, Glasser spent the prior 13 years at Biogen in the company's U.S., European and global organizations. Most recently, she served as Senior Vice President for the U.S. Alzheimer's Franchise.

    Prior to that, Glasser held a number of positions with increasing responsibility across Biogen, including:  Global Vice President and Asset Lead for Biogen's Spinal Muscular Atrophy portfolio, Global Commercial Lead for Alzheimer's, and Head of Global Marketing for Biosimilars. Glasser has also led in-line marketing teams within Biogen's U.S. Multiple Sclerosis business.

    Before Biogen, Glasser held roles of increasing responsibility in sales, market research and brand marketing with Abbott Labs, now AbbVie.

    Glasser earned her MBA in Marketing and Finance from the University of Chicago Booth School of Business and her BA with honors from Tufts University.

    Andrew Loucks will take over as Head of North America Consumer Healthcare, effective August 8. Loucks will be responsible for commercial operations in the US and Canada for Sanofi's consumer healthcare portfolio.

    Loucks joins Sanofi from Sensory Cloud Inc., where he was CEO and a Board member of the Boston-based consumer health & technology company.

    Prior to Sensory Cloud, Loucks was President of Keurig Appliances and Away From Home Coffee Systems and a member of the Keurig Dr Pepper Executive Leadership Team. Loucks also served on the Board of Directors for two early-stage entrepreneurial companies.

    Prior to Keurig Dr Pepper, Loucks was President of Frozen Foods Kellogg Company, where he was a member of the Global Leadership Team and North American Leadership Team, and previously served as the Vice President Marketing, Innovation & Nutrition for Kellogg Canada. 

    Prior to joining Kellogg Canada, Loucks spent several years working in various sales and marketing roles within Unilever.

    Loucks completed his studies in business administration at Wilfrid Laurier University, Waterloo, Canada. He also completed the General Manager/Country Manager Executive Program at Harvard Business School. 

    Bogillot, Glasser and Loucks will join Sanofi's U.S. Country Council, which will continue to be led by Carole Huntsman, Head of Specialty Care North America and U.S. Country Lead.

    About Sanofi

    We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

    Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

    Contacts 

    Evan Berland| + 1 215 432 0234 | [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/sanofi-appoints-new-heads-of-us-general-medicines-and-north-america-vaccines-and-consumer-healthcare-301599330.html

    SOURCE Sanofi

    Get the next $SNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    3/21/2025$65.00Neutral
    Goldman
    1/30/2025Sell → Hold
    Deutsche Bank
    7/26/2024$55.00 → $60.00Buy
    Argus
    1/23/2024$55.00Equal-Weight
    Morgan Stanley
    1/16/2024Buy
    UBS
    12/5/2023Overweight → Neutral
    JP Morgan
    10/30/2023Buy → Hold
    Stifel
    More analyst ratings

    $SNY
    SEC Filings

    See more
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      6/18/25 6:43:11 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      6/17/25 8:33:31 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      6/6/25 11:35:15 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

      TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

      6/9/25 10:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

      Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

      6/2/25 1:25:00 AM ET
      $BPMC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

      MORRISTOWN, N.J., May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster. New Jersey Governor Phil Murphy and Morristown officials were expected to attend the ribbon-cutting ceremony along with Sanofi CEO Paul Hudson and other senior company officials. The Morristown offices are the latest step in the delivery of Sanofi's science-driven, best-in-class workplace portfolio worldwide, notably an expansive corporate hub and R&D center in Cambridge, Massachusetts, which opened in

      5/22/25 5:30:00 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care